This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Hyaluronidase parenteral


Injections of hyaluronidase

Drugs List

  • hyaluronidase 1500unit powder for solution for injection
  • Therapeutic Indications


    Enhance permeation of local anaesthetics
    Enhance permeation of subcutaneous / intramuscular injections
    Enhance permeation of subcutaneous infusions (hypodermoclysis)
    Extravasation dispersal (when localisation is not indicated)
    Promote reabsorption of excess fluids and blood in the tissues



    Subcutaneous infusions (Hypodermoclysis)
    1500 units dissolved in 1 ml water for injection or normal saline.
    Inject into site before infusion is set up or inject into tubing of infusion set about 2 cm back from the needle at the start of infusion.
    1500 units hyaluronidase allows administration of 500 to 1000 units of most fluids.

    Subcutaneous / Intramuscular injections
    1500 units dissolved directly into solution to be injected.

    Local anaesthetics
    1500 units mixed directly with the quantity of local anaesthetic solution to be used.

    Ophthalmology local anaesthetic
    15 units of hyaluronidase per ml of local anaesthetic to be used.
    (0.01 ml of the solution reconstituted in 1 ml of solvent = 15 unit)

    Extravasation (Where dispersal rather than localisation is indicated)
    1500 units in 1 ml of water for injection or normal saline infiltrated into affected area as soon as possible after extravasation noted.

    1500 units in 1 ml of water for injection or normal saline infiltrated into affected area as soon as possible.


    (See Dosage; Adult)


    (See Dosage; Adult)


    For subcutaneous injection and infusion or intramuscular injection.

    Use immediately after reconstitution.


    None known

    Precautions and Warnings


    Administer reconstituted solution immediately
    Do not administer at site where infection is present
    Do not administer at site where malignancy is present
    Do not mix with other drugs/substances unless compatibility known
    Not to be used to reduce the swelling of bites or stings
    Do not apply direct to cornea
    Extravasation or haematoma: administer as soon as possible

    Do not use in anaesthetic procedures in unexplained premature labour.

    Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs.

    Pregnancy and Lactation


    Avoid use during pregnancy unless safer alternative.

    There is limited evidence at the time of writing on hyaluronidase's safety in pregnancy in humans or animals.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use hyaluronidase with caution in breastfeeding.

    At the time of writing it is not known whether hyaluronidase is secreted in breast milk, although it is unlikely to harm the breastfed infant.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Hypersensitivity reactions including anaphylaxis
    Irritation (localised)
    Local infection at injection site
    Oedema (associated with hypodermoclysis)
    Periorbital oedema


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2014

    Reference Sources

    Joint Formulary Committee. British National Formulary(online) London: BMJ Group and Pharmaceutical Press Accessed on 11 November 2014.

    Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.

    Summary of Product Characteristics: Hyaluronidase 1500 I.U. Powder for Solution for Injection/Infusion. Wockhardt UK Ltd. Revised April 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.